Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD

Inhaled corticosteroids (ICSs) treatment combined with long-acting β(2)-adrenoceptor agonists (LABAs) reduces the risk of exacerbations in COPD, but the use of ICSs is associated with increased incidence of pneumonia. There are indications that this association is stronger for fluticasone propionate...

Descripción completa

Detalles Bibliográficos
Autores principales: Janson, Christer, Stratelis, Georgios, Miller-Larsson, Anna, Harrison, Tim W, Larsson, Kjell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654780/
https://www.ncbi.nlm.nih.gov/pubmed/29089754
http://dx.doi.org/10.2147/COPD.S143656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654780/
https://www.ncbi.nlm.nih.gov/pubmed/29089754
http://dx.doi.org/10.2147/COPD.S143656

Ejemplares similares